NY-ESTÉE-LAUDER
12.7.2024 00:16:31 CEST | Business Wire | Press release
The Estée Lauder Companies Inc. (NYSE: EL) today announced that Tracey T. Travis, Executive Vice President and Chief Financial Officer, has decided to retire, effective June 30, 2025, after more than twelve years of exemplary leadership and service at the company. A successor for the CFO role has been identified and will be named in the coming weeks. Tracey will work closely with this person to ensure a smooth and successful transition.
“Tracey has been an invaluable business partner and a trusted advisor to me, our executives and Board of Directors, as well as a mentor and role model to many across our organization,” said Fabrizio Freda, President and Chief Executive Officer. “She has built and led a robust, integrated Global Finance & Strategy organization that has served as a valued business partner across the company and has helped to optimize delivery of our financial plans. Her financial acumen, discipline, and operational excellence have been essential to our company’s growth, and so many areas of our organization have her valuable imprint on them.”
Since joining The Estée Lauder Companies (ELC), Tracey has led the company’s Global Finance, Accounting, Tax, Treasury, Investor Relations, Information Technology, and Strategy and New Business Development organizations. Tracey has also co-led the company’s Global Value Council and served as a member of the Executive Leadership Team and the Investment Development Committee. Tracey has also been a respected and engaging leader in her extensive work with our global investor community.
Under her guidance, the company has enhanced its financial strength and flexibility, enabling us to further invest in our long-term growth drivers, such as innovation, digital transformation, emerging markets, talent development, and M&A strategy. Additionally, Tracey has played a pivotal role in leading and advancing the financial profile of our global brand portfolio.
Over the last twelve years, Tracey built a robust, integrated Global Finance & Strategy (F&S) organization at ELC that serves as a valued business partner across the company, with a particular focus on cultivating talent across the organization to bring new perspectives to the finance function. Under her leadership, F&S has provided financial guidance throughout the enterprise while maximizing business and transformational opportunities, optimizing the capital structure, and supporting brand growth strategies and cash management. Tracey leaves the F&S function a transformed organization.
Together with ELC’s senior leadership, Tracey has deeply embedded the company’s corporate strategy throughout the organization, solidifying core planning processes with an emphasis on executional excellence. Working alongside senior leadership, Tracey and her team have implemented and driven a progressive end-to-end M&A strategy and value-driven empowerment and integration, including many important strategic acquisitions and investments such as DECIEM and TOM FORD. Tracey has also led the New Incubation Ventures (NIV) team to enable the sourcing, building, and growth of the brands and business models of tomorrow.
Tracey has helped further improve and elevate the company’s Information Technology function, strengthening its competitive edge through investments in areas such as digital tech centers around the world, embodying ELC’s global approach to technology management and innovation and enhancing the diversity of its capabilities. Tracey also served as an instrumental leader in establishing the company’s shared services capability to support the business and its growth.
Tracey played a critical role in strengthening talent development and engagement by developing and growing ELC’s Finance & Strategy Leadership Development Program (FASLEAP), and guiding the function’s approach to identifying, training, and placing top talent. Tracey has also been a committed Global Executive Sponsor of the Women’s Leadership Network (WLN) employee resource group (ERG), where she helped further a culture of recognizing women as pioneers in the beauty industry and highlighting their creativity and ingenuity in shaping trends and redefining standards. She has been a passionate advocate for the company’s efforts across philanthropy, citizenship and sustainability, and inclusion, diversity and equity, including by championing initiatives to advance racial equity and representation within the company and the beauty industry.
“An inspiring and visionary leader, Tracey has been deeply committed to exemplifying our values throughout her years of dedicated service to our company,” said William P. Lauder, Executive Chairman. “Tracey has had a remarkable impact on driving our business forward by leading our portfolio strategy, but also by developing our talent, cultivating a culture of inclusion and continued learning, and advancing initiatives to foster a more diverse and equitable workplace and marketplace.”
Tracey has been honored with numerous industry awards and accolades throughout her distinguished career. She received a Best CFO award by Institutional Investor magazine, was recognized as one of the “Top 100 African Americans in Corporate America,” as well as “The Most Powerful Women in Corporate America” by Black Enterprise magazine. In 2019, she was honored with an Achiever Award by Cosmetic Executive Women. Tracey currently serves as a director on the Board of Accenture PLC and the Board of Meta Platforms Inc. (formerly, Facebook).
ABOUT THE ESTÉE LAUDER COMPANIES
The Estée Lauder Companies Inc. is one of the world’s leading manufacturers, marketers, and sellers of quality skin care, makeup, fragrance, and hair care products, and is a steward of luxury and prestige brands globally. The company’s products are sold in approximately 150 countries and territories under brand names including: Estée Lauder, Aramis, Clinique, Lab Series, Origins, M·A·C, La Mer, Bobbi Brown Cosmetics, Aveda, Jo Malone London, Bumble and bumble, Darphin Paris, TOM FORD, Smashbox, AERIN Beauty, Le Labo, Editions de Parfums Frédéric Malle, GLAMGLOW, KILIAN PARIS, Too Faced, Dr.Jart+, and the DECIEM family of brands, including The Ordinary and NIOD.
For more information, visit www.elcompanies.com.
ELC-C
ELC-L
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240711879987/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom